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Abstract 
DNA is proving to be a powerful scaffold to construct molecularly precise designer DNA devices. 
Recent trends reveal their ever-increasing deployment within living systems as delivery devices that 
not only probe but also program and reprogram a cell, or even whole organisms. Given that DNA is 
highly immunogenic, we outline the molecular, cellular and organismal response pathways that 
designer nucleic acid nanodevices are likely to elicit in living systems. We address safety issues 
applicable when such designer DNA nanodevices interact with the immune system. In light of this, 
we discuss possible molecular programming strategies that could be integrated with such designer 
nucleic acid scaffolds to either evade or stimulate the host response with a view to optimizing and 
widening their applications in higher organisms. 
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Deoxyribonucleic  acid  (DNA)  is  central  to  encoding  genetic information  in  eukaryotic  and  
prokaryotic  cells,  as  well as  in  bacteriophages  and  viruses.  DNA  also  possesses  rich diversity in 
structure and enzymatic function 1 . It is thus an ideal molecular material in which to integrate 
versatile chemical functionalities 1,2 . DNA is abundant in circulating blood in animals as a  result  of  
its  release  from  dying  cells;  cells  therefore  constantly come in contact with DNA from extraneous 
sources (referred to as foreign DNA) that they distinguish as ‘non-self’. This is distinct from 
endogenous ‘self-DNA’ or the cell’s own genomic DNA present within its nucleus. Mechanisms that 
differentiate ‘self’ from ‘non-self’ DNA are usually based on simple chemical modifications, for 
example, cytosine methylation of DNA 3 . Exogenous DNA can even function as mobile genetic 
elements and is responsible for the acquisition of genetic traits 4 . Cells are also capable of 
recombining non-self DNA with self-DNA. A proportion of non-self DNA is harmful, such  as  that  
derived  from  lytic  bacteriophages  and  viruses,  and consequently, mechanisms to rapidly detect 
and eliminate it have also evolved 5,6 . The interactions of foreign or synthetic DNA with biological 
systems are therefore multilayered, complex and lead to different outcomes. 
DNA has been widely exploited in living systems for bio medical applications  as  duplex  DNA  
(Fig.  1a)  in  the  form  of  a  synthetic carrier of genetic instructions, such as circularized plasmid 
DNA (Fig. 1b), and its nanostructured forms (Fig. 1c–g). Nanoparticulate complexes  of  plasmid  DNA  
with  non-immunogenic  polymers such as chitosan (Fig. 1c) have been used in vivo for gene delivery 
7 . Such nanoparticles are distinct from structural motifs formed by specific sequences of DNA such 
as the G-quadruplex 8  or i-motif 9  (Fig. 1d). Spherical nucleic acids (SNA; Fig. 1e) represent another 
distinct class of nanostructured DNA where single-stranded (ss) or double-stranded (ds) DNA are 
displayed on the surface of inorganic nanoparticles 10 . Importantly, due to its molecular 
programmability, DNA can be assembled into rationally designed, structurally precise architectures 
at the nanoscale that are popularly referred to as designer DNA architectures 1 . Designer DNA 
nanodevices are fabricated using either DNA tiling or DNA origami. DNA tiling exploits hierarchical 
assembly of structured DNA motifs called tiles using sticky-ended cohesion 1  (Fig. 1f). DNA origami, 
on the other hand, utilizes multiple, short ‘staple’ strands that hybridize with domains on  a  large  
viral-genome-derived  ssDNA  scaffold,  folding  it  into precise super-architectures 11  (Fig. 1g). 
Importantly, designer DNA architectures present great potential to probe and program living 
systems 2 . However, before their successful and wide implementation in higher organisms, it is 
important to consider the various cellular and systemic responses that such DNA architectures might 
elicit. 
In this Perspective, we discuss examples of DNA nanodevices that  have  been  deployed  in  
multicellular  organisms  and  their modes of introduction. Even though DNA is a natural biopolymer, 
when present at the wrong place at the wrong time it can elicit a strong inflammatory reaction. We 
summarize how cells respond to exogenous or endogenous DNA to better understand and possibly  
anticipate  host  responses  to  designer  DNA  nanodevices. Finally, we outline potential design 
considerations and immediate challenges that impact the delivery of DNA nanodevices and the 
corresponding host response with a view to improving tolerance, thereby promoting their wider use. 
Biological responses to DNA in higher organisms 
Cells protect self-DNA against foreign DNA using surveillance systems that detect non-self DNA and 
trigger mechanisms for their swift elimination. For example, in bacteria and archaea, sequence-
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independent and sequence-specific restriction mechanisms 5,6 , and the  memory-based  adaptable  
CRISPR/Cas  (clustered  regularly interspaced  short  palindromic  repeats/CRISPR  associated  
complex) 12  systems direct endonuclease activity against foreign DNA. Thus  DNA-based  early  
immune  systems  evolved  from  bacteria, diversified in eukaryotes, and are at the heart of 
mammalian responses to natural DNA. 
DNA viruses and bacteriophages are detected by direct binding of their DNA to one or more 
receptors in the host cell they infect. Therefore when exposed to natural or synthetic nucleic acids, 
cells respond as they do to viral infection 13 . Eukaryotic cells respond to DNA in two ways; (i) by 
upregulating interferon (IFN) genes, and (ii) stimulating caspase-1 protease activity through 
inflammasome signalling pathways 14 . Detection of DNA converges on upregulationand secretion of 
type I IFNs (IFN-α and IFN-β) 14,15 . Secreted IFNs induce the expression of a large number of IFN-
stimulated genes, many  of  which  have  broad  antiviral  and  inflammatory  roles 15 . DNA-
dependent  activation  of  caspase-1  inflammasomes  results  in the release of cytokines, such as 
interleukin-1β and interleukin-18, which have antimicrobial as well as pro-inflammatory properties 
16,17 . Defined  inflammatory  responses  to  DNA  facilitate  the  long-term adaptive immune 
response to infection. This feature is exploited in DNA-based vaccines to boost immunity 18 . In 
other settings, however, chronic expression of IFNs and activation of caspase-1 cause inflammatory 
tissue damage in the host 19 . Thus, like natural DNA, synthetic DNA nanodevices too are likely to 
elicit an overall inflammatory and antiviral-like response from the host. 
Host  cells  detect  exogenous  DNA  that  is  extracellular,  vacuolar  or  cytoplasmic  using  >20  
different  receptor  proteins 14,19 .  The majority elicit IFN secretion, and one (AIM2) directly 
activates caspase-1 (ref. 20; Fig. 2). Only major DNA receptors are discussed here to provide an 
overall view of the complex system. For example, dsDNA in the cytosol is bound by receptors such as 
IFI16, DDX41, cGAS, MRE11 and DNA-PK; all induce IFNs via a protein called STING 14,21  (Fig. 2). On 
binding cytosolic DNA, cGAS synthesizes a newly identified second messenger — 2ʹ,3ʹ-cGAMP (cyclic 
[G(2ʹ,5ʹ)pA(3ʹ,5ʹ)p]) — that allosterically activates STING to enhance IFN responses 22–24  (Fig. 2). 
Interestingly, A:T-rich dsDNA in the cytosol can be transcribed by RNA polymerase III into 5ʹPPP-
containing RNA  that  induces  IFN  expression  by  binding  the  RIG-I  dsRNA receptor 25 . The 
protein LRRFIP1 binds cytosolic DNA and induces IFNs via a novel β-catenin pathway 26 . Post 
endocytosis into vacuoles, dsDNA containing umethylated CpG motifs is detected by the TLR9 
receptor that induces the expression of IFNs independently of STING 14,21  (Fig. 2). 
Little is known about nucleotide modifications that affect receptor binding and downstream 
signalling. One could speculate that self-DNA  is  protected  from  cytosolic  DNA  sensors  via  
compartmentalization into the nucleus, whereas RNA sensors detect specific  ‘foreign’  chemical  
modifications  of  RNA  distinguishing   it from  host  mRNA.  Differential  methylation  and  
secondary  structures  of  dsDNA  elicit  differential  responses  via  the  TLR9  receptor. The 2ʹ-
deoxyribose sugar is an important determining factor in  the  context  of  backbone  chemistry  
(phosphodiester  versus phosphorothioate) in two ways. First, ribose sugars are not tolerated on 
TLR9 ligands. Second, abasic as well as non-CpG-motif-containing  2ʹ-deoxyribose  phosphodiester  
chains  activate  TLR9, whereas similar phosphorothioate chains inhibit TLR9 27,28 . In the case of 
the cytosolic AIM2 receptor, sequence-independent detection of ~80 bp dsDNA results in its 
oligomerization and activation of caspase-1 (ref. 29). In addition, cytosolic DNA receptors might 
detect oxidation-damaged DNA more readily 30 . 
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The  cellular  responses  to  DNA  also  depend  on  the  cell  type involved;  plasmacytoid  dendritic  
cells  (pDCs),  myeloid  DCs (mDCs) and macrophages and T- or B-lymphocytes express different 
sensors for DNA and thus respond differently 31 . For example, in the case of TLR9, pDCs secrete 
large amounts of IFN-α when exposed to CpG oligonucleotides, which spontaneously form nano-
particles as a result of G-tetrad formation (called Class A CpG) 28,30 . TLR9  activation  of  B  cells  by  
CpG  oligonucleotides  devoid  of complex secondary structures (Class B CpG) leads to cell 
proliferation 28 . Further, mDCs that detect non-CpG dsDNA via TLR9 trigger suppressor T-cell 
responses 32 . CpG DNA when presented in synthetic motifs such as SNAs (Fig. 1e) are far more 
potent stimulators of TLR9 responses than the corresponding ssDNA. This underscores the interplay 
of DNA structure and cell type in generating an activating or suppressive biological response 33 . 
Homeostatic  mechanisms  prevent  unnecessary  activation  of DNA responses by prompt disposal 
of cellular DNA at the end of its life cycle 34,35  (Fig. 2). The importance of DNAses is revealed in 
hereditary autoinflammatory syndromes where high levels of circulating DNA  are  seen,  such  as  
systemic  lupus  erythematosus 36 ,  Aicardi–Goutières  syndrome 37   and  rheumatoid  arthritis 38 .  
Mutations  in DNAse I (encoded by the gene DNASE1) and DNAse III (encoded by  TREX1)  result  in  
increased  circulating  DNA  and  IFN  expression 37,39,40 . DNAse I, a secreted enzyme, degrades 
DNA from ingested food as well as that in blood. Reduced DNAse I activity can result in lupus, a 
disease that shows features of increased IFN production 41,42 . Similarly, loss of TREX1 results in the 
accumulation of ~60 b long ssDNA,  which  drives  IFN-dependent  pathology 37,39 .  Likewise, 
DNAse II (encoded by Dnase2a) deficiency in mice results in IFN-driven autoimmunity, which is 
reversible if mice are also deficient in IFN receptors or Sting 43,44 . Therefore successful DNA 
scaffolds must not only fly under the radar to avoid activating antiviral-like inflammatory responses, 
but must also be amenable to natural and safe disposal from biological systems post-deployment. 
Thus DNA nanodevices need to incorporate design principles to navigate the multilayered detection 
and defense machinery of higher organisms. 
Designer DNA nanodevices in vivo 
A  selection  of  designer  DNA  nanodevices  have  been  used  either as  drug-delivery  vehicles  or  
diagnostic  probes  in  living  systems 2 . Although several nanodevices have been applied to cells in 
culture, their application in multicellular organisms has only just emerged. This is primarily due to 
major molecular barriers faced in vivo such as (i) efficient delivery and targeting to the site of 
interest, (ii) stabilityof externally introduced DNA nanodevices, and (iii) their potential toxicity in the 
host organism. Of the limited number of nanodevices deployed  in  vivo,  the  DNA  icosahedron  and  
tetrahedron  present good case studies to discuss these molecular barriers 45,46 . 
Currently,  in  vivo  delivery  strategies  predominantly  rely  on injections  to  target  DNA  
nanodevices  to  specific  cell  types.  The first study of a designer DNA architecture in a multicellular 
living organism used a pH-sensitive DNA nanodevice, the I-switch, which was microinjected into 
Caenorhabditis elegans; post-injection, the I-switch was targeted to specific scavenger cells that 
displayed cell-surface anionic ligand-binding receptors (Fig. 3a; left panel). Once internalized, it was 
shown that the nanodevice could probe endosomal maturation 47 . This same strategy was 
exploited to introduce a cargo-loaded DNA icosahedron to scavenger cells, where both cargo 
functionality  and  device  integrity  were  quantitatively  preserved post-delivery 45,48  (Fig. 3a; right 
panel). 
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In mammalian systems, DNA architectures have been delivered intravenously.  A  general  design  
principle  for  targeting  the  nanostructure to the site of interest exploits the display of specific 
ligands on the nanodevice that enables its binding to a cell-specific endogenous  receptor,  leading  
to  its  cellular  uptake.  By  exploiting  the overexpression of the folate receptor on cancerous cells, it 
was possible to target tetrahedral DNA nanoparticles bearing folate moieties and short interfering 
RNA (siRNA) to xenograft tumours in nude mice 46  (Fig. 3b; left panel). Post-internalization, the 
siRNA reduced the expression level of a target gene 46 . However, despite their enrichment in the 
tumour, some DNA nanoparticles could also be uptaken by non-cancerous cells bearing the folate 
receptor, given its ubiquitous expression across tissues 49 . Nevertheless, this strategy seems 
promising to target selected malignancies. Another example is the in vivo delivery of a tetrahedral 
DNA device displaying antigens and adjuvants to produce antibodies 50 . A model antigen 
(streptavidin) and  adjuvant  (CpG  deoxyoligonucleotides)  were  assembled  on  a DNA tetrahedron 
and injected into a mouse. Identification of the DNA–streptavidin–CpG complex by circulating 
macrophages and dendritic cells in the bloodstream led to the production of anti bodies against 
streptavidin 50  (Fig. 3b; right panel). 
Among diverse delivery modes, oral administration is popular in various model organisms, yet 
surprisingly has not been adopted thus far for DNA nanostructures, probably due to the high 
susceptibility of DNA to acid-catalysed depurination and nucleases, and its  low  efficiency  in  
traversing  tissue  barriers.  Often,  therapeutic proteins or peptides are packaged within liposomes, 
nano particles, dendrimers or micelles to protect against proteolysis and low gastrointestinal pH 
51,52 . Intranasal delivery presents exciting possibilities. The  high  surface  area  and  permeability  
of  the  nasal  endo  thelial membrane  promote  rapid  absorption  and  decreased  metabolism of 
the applied nanoparticles 53 . Further, intranasal administration is user friendly and relatively non-
invasive. It also provides access to the mammalian central nervous system, through mechanisms that 
are not yet well understood 54 . For example, plasmid DNA coated with a polycationic lysine 
derivative has been delivered intranasally in rats where it led to green fluorescent protein 
expression in the brain 55 . Other routes to access a specific tissue involve direct injections at the 
target site, most notably injections of chitosan–DNA nanoparticles into the mouse eye 56,57  and 
lung 58  as well as the rat brain 59  and liver 60 . Direct tissue injections present good potential as 
they provide high local concentrations and therefore minimize toxicity, but are invasive and require 
special expertise. Importantly, regardless of the delivery route, DNA nanostructures are likely to 
elicit an immune response that would need to be either exploited or mitigated depending on the 
functionality of the architecture — for example, vaccine or therapeutic cargo. 
Without  robust  targeting  technology,  there  is  a  risk  of  nonspecific  nanodevice  delivery  to  
undesired  sites.  Cell-specific  targeting  of  DNA  nanodevices  has  been  achieved  using  
specificligand–receptor  pairs,  where  the  DNA  architecture  enters  cells via  receptor-mediated  
endocytosis 61 .  Newer  strategies  that  leverage  cancer  cell  surface-expressed  biomarkers 62 ,  
endogenously expressed tissue-specific receptors 45,47 , synthetic recombinant antibodies 63  or 
aptamers 64  need to be devised to achieve efficient targeting. For example, the ERBB receptor 
could be a promising route for anti-cancer DNA nanodevices in the future 62 . The anionic ligand-
binding receptors that have high affinity for DNA present another viable option. Synthetic protein–
DNA partners also present exciting  possibilities.  For  example,  a  recombinant  antibody  fused  to 
Furin, a trans-Golgi network trafficking protein, has been used to achieve  organelle  targeting  in  
cells 63 .  This  recombinant  antibody recognized a specific 8-mer dsDNA sequence on the 
Surana et al. Nat Nanotechnol, DOI: 10.1038/NNANO.2015.180 
6 
 
nanostructure and was able to target it to the trans-Golgi network 63 . Although mechanisms of 
cytosolic delivery of DNA via receptor-mediated endocytosis, as seen with lipid-complexed DNA 65 , 
remain unclear, these  could  be  leveraged  in  future  to  deliver  DNA  nanodevices cytoplasmically.  
Nanodevices  enter  cells  through  different  endocytic  mechanisms,  and  how  these  different  
entry  mechanisms could  affect  efficacy  and  stability  of  DNA  devices  remains to be addressed. 
Given that there are several mechanisms that dispose of superfluous DNA to maintain homeostasis, 
the efficacy and stability of the DNA nanodevice need to match the application for which it is 
designed. Systemic circulatory stability depends on complex factors such as digestion by extracellular 
DNAses, size and possibly shape of DNA nanodevices, tissue uptake and removal from circulation by 
the kidneys and liver. While it is known that size or shape of nanostructured gold, carbon, silica, 
dendrimers, quantum dots, liposomes and  polymeric  particles  affect  their  in  vivo  clearance  
times 52   and uptake 66 ,  analogous  studies  on  designer  DNA  nano structures remain  to  be  
performed.  Cellular  stability  of  DNA  nanodevices could be altered by tuning delivery pathways 
that circumvent lysosomal delivery 61 . Further, partially dissociated nanostructures could trigger 
stronger immune responses, greater off-target effects and elevated toxicities. Thus nanostructure 
stability and nanodevice uptake pathways will cumulatively impact their bioavailability. 
One of the earliest studies that addressed DNA nanodevice stability in a multicellular organism 
exploited the scavenger cells of C. elegans to investigate DNA nanostructure clearance by lysosomal 
degradation 48 . Here, a DNA duplex displaying two single-stranded domains showed an in vivo half-
life of 8 hours. Reducing the number of single-stranded domains on the nanostructure increased its 
half-life to 11 hours. On the other hand, an architecture such as a DNA icosahedron, devoid of free 
termini, was recalcitrant to lysosomal degradation over 24 hours of investigation 48 . It has also 
been shown that fluorescently labelled DNA tetrahedra remained stable up to 48 hours post-
transfection in cultured human embryonic kidney (HEK) cells 67 . One of the reasons for increased 
in vivo stability of architectures such as the icosahedron and tetrahedron is that the Mg 2+  
requirement 67,68  for their structural integrity is relatively low and corresponds to physiological 
concentrations (1–2 mM Mg 2+ ) 69 . In this case, the Mg 2+  is needed to primarily stabilize their 
constituent N-way junctions. However, this is not the case for most DNA origami-based structures, 
where phage ssDNA is folded into DNA helices that are packed lengthwise 11 . Such packing requires 
high concentrations (10–80 mM) of divalent cations, such as Mg 2+ , to lower the  Debye  screening  
length  and  stabilize  the  overall  architecture in vitro 70,71 . When introduced into biological 
systems, where physiological  Mg 2+   concentrations  are  at  least  tenfold  lower 69 ,  these 
architectures are destabilized. As shown by Hahn et al., DNA origami-based octahedra, nanotubes 
and nanorods show low stability in fetal bovine serum (FBS) as well as in cell lines such as mouse 3T3 
fibroblasts, HEK-293 and human H441 adenocarcinoma 72 . Further, the  low  yields  of  complex  
origami-based  nanostructures  results in  molecularly  heterogenous  populations  in  bulk 73,74   
and  pose additional impediments to more widespread applications in vivo. Importantly,  increased  
stability  has  been  demonstrated  by  incorporating a surface lipid coating on DNA origami-based 
octahedra in a mouse model 75 , highlighting a strategy to increase the in vivo stability of DNA 
origami-based nano devices (Fig. 4(i)). 
The  current  knowledge  of  host  responses  to  dsDNA  can  be leveraged  to  design  DNA  
nanodevices  that  either  evade  or  activate  the  immune  response  by  tuning  their  in  vivo  
stability.  Fully ligated architectures, with minimal single strands and free termini, might show 
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enhanced stability and resistance to cellular nucleases (Fig. 4(i)). This was borne out in vitro on 
ligated polyhedra 76  and later confirmed in vivo 48 . Second, within a given architecture, the spatial 
position and accessibility of a sequence governs its vulnerability to nuclease digestion. It has been 
shown that sequences placed near three-way junctions in a tetrahedron were more resistant to 
nucleases 77 . This implies that the stability of a nanostructure can be tuned by varying the degree of 
accessibility of its vulnerable sites to either enhance its in vivo half-life or to promote its degradation 
to facilitate a payload release (Fig. 4(ii); blue region). Third, chemical modifications of the DNA 
scaffold could also make it recalcitrant to degradation. For instance, the stability of a triangular DNA 
prism in FBS could be enhanced using hexaethylene glycol- and hexanediol- modified 
phosphoramidites at the 5ʹ and 3ʹ termini of component oligonucleotides 78 . In addition, a 
covalently linked base pair between 5-formyluracil and 5-aminocytosine via Schiff base formation 
has been developed (Fig. 4(iii); top chemical structure). DNA duplexes containing  this  base  pair  are  
stable  under  denaturing  conditions and dissociate only at high temperatures 79 . Another novel 
strategy that crosslinks duplex DNA to enhance structural stability utilizesan  aniline-derived  DNA  
heterobase  and  (hydroxy)benzaldehyde. This is similar to an A–T base pair that can be reversibly 
crosslinked (Fig. 4(iii); bottom chemical structure) and was used to enhance the half-life of a DNA 
duplex in vitro 80 . 
Another  strategy  to  evade  enzymatic  cleavage  of  DNA  nano-structures  is  to  use  unnatural  
nucleic  acid  analogues  that  have modified chirality such as L-DNA 81  (Fig. 4(iv); left chemical 
structure), modified backbones such as peptide nucleic acid 82  (Fig. 4(iv);  right chemical structure), 
or modified sugar residues such as locked nucleic acids (LNA), morpholinos and bridged nucleic acids 
(PNA) 83 . These unnatural analogues are not substrates for endo  genous nucleases and could 
prolong nanodevice lifetimes, yet affording essentially identical functionality. For instance, it has 
been shown that the incorporation of 2ʹ fluoro RNA in the viral phi29 DNA-packaging RNA sequence 
yields an RNA device that was stable in RNAse A as well as in FBS over 36 hours and, further, could 
effectively gear the phi29 motor to package the viral DNA and produce infectious particles 84 . 
Chimaeric nucleic acid duplexes, such as PNA–DNA 85 , RNA–DNA 86  or LNA–DNA 87 , can be 
further used to fabricate architectures with enhanced stabilities. Such approaches however, are yet 
to be embraced widely in the field given the prohibitively high cost of their syntheses. 
An important property of nanostructured DNA scaffolds is their propensity to induce antibody 
responses. An example is the use of a tetrahedral DNA nanodevice as an adjuvant in vertebrates that 
produced antibodies against an antigen of choice 50 . Another example is a 30-helix, hollow DNA 
origami tube, which when coated with CpG motifs potently activated immune cells in a TLR9-
dependent manner 88 . This has also been observed with CpG-motifs presented on SNA that elicited 
better antibody responses and tumour regression in mice compared with their ssDNA counterparts 
33 . Given that such immunostimulatory or immunoregulatory DNA nanodevices outperform  
unstructured  or  polymer-coated  stimulatory  DNA,  they could become important in prophylaxis, 
therapeutics and possibly even  transform  vaccine  biology 89 .  Conversely,  DNA  nanodevices 
could also be designed to potentially suppress immune responses, which would be useful in contexts 
such as uncontrolled inflammation. Regulatory T cells are suppressor cells that dampen immune 
responses and can be elicited using optimized CpG-free, polymer-complexed  DNA  nanostructures 
32,90 .  In  addition,  single-stranded phosphorothioate  oligonucleotides  with  four  TTAGGG  motifs 
can directly bind AIM2 and IFI16 and prevent inflammasome signalling, and may be a starting point 
to find specific inhibitors of these pathways 91 . 
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While  the  above  applications  leverage  immune  responses  in complex  mammalian  systems,  
simpler  invertebrate  models  offer the power of genetics for more fundamental studies on the 
interaction of nanostructured DNA scaffolds with the innate immune system. For example, 
C. elegans or Drosophila melanogaster, which lack acquired immunity and some of the DNA 
receptors found in mammals but maintain humoral and innate immune responses, are excellent test 
beds to apply DNA nanodevices as probes and tools 92,93 . However,  the  genetically  tractable  
zebrafish ( Danio  rerio),  which harbours both an innate and adaptive immune response as well as 
the IFN-response system, may eventually prove to be a better model system 94,95 . Importantly, it is 
also known that not all DNA sequences are equally immunogenic. Therefore, screens to identify 
sequences of low (or enhanced) immunogenicity should better inform nanostructure  design  to  
fine-tune  immune  responses  (Fig.  4(v),(vi)). Further, immune responses are likely to be species-
specific, as has been observed in the case of differential immunomodulatory effects of DNA on 
human versus mouse cells 28 . 
Outlook and summary 
We  envision  that  the  next  generation  of  biologically  smart  DNA nano devices would need to 
incorporate an additional layer of design. These  would  leverage  size  and  shape  information  to  
achieve  precise  targeting  and  clearance  properties,  exploiting  sequences  with custom-designed 
host immune responses. Such nanodevices could act as smart cargo carriers that, as a function of 
molecular logic, can either be destabilized or remodelled to release their cargo. Although there are 
rare examples of conditional cargo release from DNA nano-devices albeit in vitro 96–98 , there is 
paucity of information on the effects of DNA sequence, nanostructure size and shape on their 
immunogenicity and in vivo clearance of the resultant DNA nanostructures in any organism. These 
data would improve our understanding of basic DNA sequence requirements to develop design 
criteria that can rationally tune biological nanodevice functionality such as stability or 
immunogenicity. Even the latest sequence design programmes 99,100  consider only architectural 
shape and flexibility of DNA nanodevices.Such next-generation designer DNA nanodevices with 
customized  host  responses  would  find  tantalizing  applications  in  drugdelivery. Given that 
responses of individual subjects to DNA differ greatly, one can envisage DNA nanodevices 
engineered for personalized immunotherapy. The capacity to cell-specifically deliver DNA  
architectures  and/or  achieve  molecular-logic-guided  cargo release  could  enable  cellular  
programming  and  reprogramming. More excitingly, in the longer term, the delivery of DNA or RNA 
cargo encoding transcription programs, which bypass the immune system,  could  be  used to 
remodel synapses  to  alter  learning  and memory, or for tissue regeneration, or building organoids 
from single cells. To fully harness the potential of the DNA scaffold in vivo, the next layer of design in 
DNA nanodevices needs strategies to leverage  endogenous  surveillance  mechanisms  to  maximally  
tap nano device functionality. 
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Figures  
 
Figure 1  
 
 
DNA and its various nanostructured forms. a, Duplex DNA is widely exploited in therapeutics and 
biomedical applications in the form of diverse nanostructures. b, Circularized elements such as 
plasmids are routinely used for gene expression. c, Plasmids are often complexed with non-
immunogenic polymers such as chitosan or polyethylene glycol (green) to enhance gene delivery. d, 
Structural motifs such as G-quadruplexes are formed by specific sequences of DNA in response to 
chemical triggers such as ions and pH. e, Spherical nucleic acids are fabricated by immobilizing 
single-stranded or duplex DNA (green strands) on the surface of inorganic nanoparticles (brown 
core). f, Designer DNA nanodevices are formed by assembling rationally designed DNA motifs with 
sticky ends (top). The DNA buckyball structure (bottom) is ~80 nm in diameter. g, DNA origami-based 
nanodevices use several staple strands (blue and orange) to fold a large viral genome-derived DNA 
strand (grey) into defined super-architectures that can be used to deliver molecular payloads (yellow 
and pink). Figure reproduced with permission from: d, ref. 8, Nature Publishing Group; e, ref. 10, 
American Chemical Society; f, ref. 101, Nature Publishing Group; g, ref. 96, AAAS. 
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Figure 2  
 
 
Natural mechanisms to detect and dispose of foreign DNA by host cells. Several cytosolic receptors, 
such as IFI16, MRE11, DNAPK, DDX41 and cGAS, detect DNA in the cytosol, directly bind duplex DNA 
(dsDNA) and trigger transcription of type I interferons (IFNs), which in turn upregulate various 
interferon-stimulated genes (ISGs). These cytosolic receptors induce IFNs via the protein STING. 
cGAS binds DNA and synthesizes a novel second messenger — 2’,3’-cGAMP (cGAMP) — that 
activates STING. RNA polymerase III (POL III) transcribes DNA into RNA that binds the RNA receptor 
RIG-I, and induces IFNs independently of STING. LRRFIP1 receptor induces IFNs via β-catenin (β-cat). 
The AIM2 receptor binds DNA and assembles inflammasome platforms activating caspase-1 (CASP1). 
Caspase-1 controls the release of proinflammatory cytokines and triggers cell death. dsDNA can also 
be detected within endosomes (pink filled circles) by TLR9, which activates IFN expression. dsDNA is 
disposed of extracellularly by DNAses (such as DNAse I) or within lysosomes, for example by TREX1. 
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Figure 3  
 
 
Targeting and delivery of DNA nanostructures in vivo. a, Microinjection-mediated introduction of a 
pH-sensitive DNA nanodevice (left) and a cargo-loaded DNA icosahedron (yellow spheres; right) in 
C. elegans uses the anionic ligand-binding receptors (red, bottom) to achieve cell-specific targeting. 
The red star and red and blue circles represent fluorophores. b, The DNA tetrahedron, bearing folate 
moieties (grey triangles) and siRNA (purple duplex) on its surface (left), was targeted to murine 
tumours overexpressing the folate receptor (red). The DNA tetrahedron was also used as a scaffold 
to display streptavidin (red ovals) as an antigen and single-stranded CpG oligonucleotides (purple 
strands) as an adjuvant (right), which was introduced via venous injections into the mouse 
bloodstream. Internalization of the DNA tetrahedron into B-cells (blue) and macrophages (green) 
leads to downstream activation of T cells (red), which in turn activate synthetic antibody production 
against streptavidin by B cells. Figure reproduced with permission from: a(left), ref. 47, Nature 
Publishing Group; a(right), ref. 45, Nature Publishing Group; b(left), ref. 46, Nature Publishing Group; 
b(right), ref. 50, American Chemical Society. 
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Figure 4  
 
 
Strategies to tune stability of designer DNA nanodevices to tailor host immune responses. DNA 
architectures devoid of nicks or single-stranded domains show increased stability in vivo, which can 
be enhanced by encapsulation in non-immunogenic polymers (i). Positioning nuclease-sensitive 
sequences (blue region; ii) near N-way junctions decreases susceptibility to nucleases (blunt blue 
arrows). Incorporation of modified, chemically crosslinkable nucleobases (green region; iii) could 
enhance duplex stability in vivo. Top and bottom chemical structures show examples of crosslinkable 
nucleobases 79,80 . Non-natural nucleic acid analogues (red; iv), such as L-DNA (left chemical 
structure) and peptide nucleic acid (right chemical structure), are not substrates for endogenous 
nucleases. Immunogenicity of a designer DNA nanodevice could be lowered by structurally shielding 
sequences of high immunogenicity (magenta regions; v), and exposing sequences of low 
immunogenicity (orange regions; vi) to the external milieu. Part (i) reproduced with permission from 
ref. 102, AAAS. 
